Firefly Neuroscience is collaborating with Prof. Dr. med. Christian Schaaf of Heidelberg University Hospital on a study investigating the neurophysiological effects of 15q13.3 copy number variants (CNVs). The study will analyze EEG data from 30 subjects using Firefly’s FDA-cleared BNA platform and aims to identify electrophysiological biomarkers associated with these CNVs, characterize neurocognitive profiles, and inform future diagnostic and therapeutic strategies for neurodevelopmental disorders. This collaboration expands on previous work between Firefly and Prof. Schaaf.
This research is crucial for advancing the understanding of 15q13.3 CNVs and their impact on brain function. The identification of specific biomarkers could lead to earlier and more accurate diagnoses of related neurodevelopmental disorders, paving the way for timely interventions and personalized treatment strategies. The study’s focus on both deletions and duplications within the 15q13.3 region allows for a nuanced understanding of the distinct neurocognitive profiles associated with each variation, furthering precision medicine in this area.
The study, scheduled to continue through 2026, utilizes Firefly’s FDA-cleared EEG systems and its proprietary normative database. Firefly is providing full analytical support, including training, throughout the study’s duration. This represents a significant commercial engagement for Firefly, aligning with its growing focus on building a licensing business. The collaboration also leverages the expertise of a renowned expert in the field of human genetics, further validating the potential of Firefly’s technology.
This collaboration signals a growing trend toward utilizing objective measures of brain activity, such as EEG, in various stages of product development within the pharmaceutical and medical technology sectors. The study’s findings hold the potential to accelerate the development of targeted therapies for neurodevelopmental disorders and solidify Firefly’s position as a leader in AI-driven brain health solutions. Furthermore, the insights gained from studying rare genetic variants like 15q13.3 can illuminate the broader landscape of neurodevelopmental and neuropsychiatric disorders, ultimately leading to more effective care for a wider patient population.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
